Development of novel N-(6-methanesulfonyl-benzothiazol-2-yl)-3-(4-substituted-piperazin-1-yl)-propionamides with cholinesterase inhibition, anti-β-amyloid aggregation, neuroprotection and cognition enhancing properties for the therapy of Alzheimer's disease-Reference-Cited by-同舟云学术

Development of novel N-(6-methanesulfonyl-benzothiazol-2-yl)-3-(4-substituted-piperazin-1-yl)-propionamides with cholinesterase inhibition, anti-β-amyloid aggregation, neuroprotection and cognition enhancing properties for the therapy of Alzheimer's disease

Published:2020 Issue:30 Volume:10 Page:17602-17619
ISSN:2046-2069
Container-title:RSC Advances
language:en
Short-container-title:RSC Adv.

Author:

Mishra Chandra Bhushan¹²³⁴,Shalini Shruti¹²³⁴,Gusain Siddharth¹²³⁴,Prakash Amresh⁵⁶⁷⁴^ORCID,Kumari Jyoti¹²³⁴,Kumari Shikha¹²³⁴,Yadav Anita Kumari¹²³⁴,Lynn Andrew M.⁸⁹¹⁰⁴,Tiwari Manisha¹²³⁴^ORCID

Affiliation:

1. Dr. B. R. Ambedkar Centre for Biomedical Research

2. University of Delhi

3. New Delhi 110007

4. India

5. Amity Institute of Integrative Sciences and Health (AIISH)

6. Amity University Haryana

7. Gurgaon-122413

8. School of Computational & Integrative Sciences

9. Jawaharlal Nehru University

10. New Delhi 110067

Abstract

A novel series of benzothiazole–piperazine hybrids were rationally designed, synthesized, and evaluated as multifunctional ligands against Alzheimer's disease (AD).

Funder

Ministry of Health and Family Welfare

Department of Health Research, India

University of Delhi

Ministry of Ayurveda, Yoga and Naturopathy, Unani, Siddha and Homoeopathy

University Grants Commission

Department of Science and Technology, Ministry of Science and Technology, India

Publisher

Royal Society of Chemistry (RSC)

Subject

General Chemical Engineering,General Chemistry

Link